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Abstract
Objectives: To estimate the cost and patterns of expenditure of dry eye treatment.
Methodology: We retrieved data on the type and cost of dry eye treatment in Singapore National Eye Centre from
pharmacy and clinic inventory databases over a 2 year period (2008–2009) retrospectively. According to the type of
treatment, data were sorted into 7 groups; meibomien gland disease (MGD) treatment, preservative free lubricant eye
drops, preserved lubricant eye drops, lubricant ointments and gels, cyclosporine eye drops, oral supplements and non-
pharmacological treatments/procedures. Each recorded entry was considered as one patient episode (PE). Comparisons in
each group between two years were carried out using Pearson Chi-Square test. Significance level was set at alpha =0.05.
Results: Cost data from 54,052 patients were available for analysis. Total number of recorded PEs was 132,758. Total annual
expenditure on dry eye treatment for year 2008 and 2009 were US$1,509,372.20 and US$1,520,797.80 respectively. Total
expenditure per PE in year 2008 and 2009 were US$22.11 and US$23.59 respectively. From 2008 to 2009, there was a 0.8%
increase in total annual expenditure and 6.69% increase in expenditure per PE. Pharmacological treatment attributes to
99.2% of the total expenditure with lubricants accounting for 79.3% of the total pharmacological treatment expenditure.
Total number of units purchased in preservative free lubricants, cyclosporine eye drops and MGD therapy have increased
significantly (p,0.001) whereas number of units purchased in preserved lubricants and ointments/gels have reduced
significantly (p,0.001) from 2008 to 2009.
Conclusion: Dry Eye imposes a significant direct burden to health care expenditure even without considering indirect costs.
Health care planners should be aware that these direct costs appear to increase over the time and more so for particular
types of medications. Given the limitations of socio-economic data, true societal costs of Dry eye syndrome are likely to be
much higher than estimated.
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Introduction
Dry eye syndrome (DES) is a multifactorial chronic disease that
affects millions of people over the world with significant socio-
economic implications, including expenses associated with in-
creased health care utilization (e.g. medication and physician visits)
and impact on daily social and physical functioning, work place
productivity and quality-of-life [1–4].
Traditional treatment for DES has been largely palliative with
over the counter lubricating eye drops or artificial tears. Increase
in knowledge of patho- physiology of DES has led to tremendous
advances in treatment in the last two decades. Lately, with
introduction of newer modalities such as topical cyclosporine
emulsion [2,5,6], mucomimetic drugs and oral supplements [2,7]
which have substantial acquisition price, the burden of patient’s
pharmacy budget has significantly increased6. Extensive cost of
dry eye treatment may affect compliance to treatment, the choice
of medication by clinicians, stocking of medication in hospitals,
and the possibility of medications to be listed in standard
formulary.
Evaluating cost effectiveness of dry eye treatment is quite
challenging due to the multifactorial nature of the disease and
potential limitations of techniques available to evaluate therapeutic
outcomes of multi-palliative treatment modalities used. In US cost
of managing dry eye patients in health care organizations is
estimated at US$700,000 per million patients [8]. There are large
variations in the dry eye treatment costs between countries in
Europe [9]. The absolute costs may be much higher for the Asian
population as the prevalence rates of dry eye in Asian population is
higher (30%) compared to predominant Caucasian populations
(15%) [8].
There is lack of published data on healthcare resource
utilization in managing DES in Asian countries. In this study we
report the cost and patterns of expenditure of dry eye treatment in
a Singapore population.
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Study Design
This is a retrospective cost analysis study.
Methods
We retrieved the data retrospectively on type and cost of dry eye
treatment prescribed by ophthalmologists in Singapore National
Eye Centre (SNEC) from pharmacy and clinic inventory databases
over a 2 year period (2008–2009). SNEC is the designated national
centre for tertiary eye care services in Singapore which currently
manages an annual workload of 250,000 outpatient visits, which
amounts to around 60% of the overall eye care in the public
sector. (Available: http://www.snec.com.sg/about/history/
Pages/home.aspx, http://www.snec.com.sg/about/
achievements/Pages/home.aspx).
We included cost data on dry eye treatment of all the patients
that attended the outpatient eye clinics in SNEC from year 2008
to 2009 in our analysis. Data on prescription drugs purchased
elsewhere other than SNEC pharmacy were not captured.
According to the type of treatment, data were sorted into 7
groups; Group A: Treatment for meibomian gland disease (MGD),
Group B: Preservative free lubricant eye drops, Group C:
preserved lubricant eye drops, Group D: lubricant ointments
and gels, Group E: Cyclosporine eye drops, Group F: Oral
supplements Group G: Non pharmacological treatments/proce-
dures.
Treatment for MGD included warm compress with eye masks
and lid hygiene with BlephagelH (Spectrum Thea Pharmaceuticals
Limited, Fernbank House, Cheshire, UK) or Lid-CareH (Novartis
International AG, Basel, Switzerland) cleaning solutions. Non
pharmacological treatment/procedures included tear retention
methods such as punctum plug, punctum cautery and tarsorrha-
phy. (Table 1) Each recorded entry was considered as one patient
episode (PE). In order to calculate the patient episodes, repeated
visits by the same patient was identified by sorting the entries by
patients ID and deleting the duplicates.
Comparisons in each group between two years were carried out
using Pearson Chi-Square test. Significance level was set at alpha
=0.05.
Results
Cost data from 54,052 patients were available for analysis, from
2008–2009. Over this period (2008–2009), the total number of
recorded patients’ episodes was 132,758. Figure 1 shows monthly
distribution of total expenditure on dry eye related medications
and procedures in 2008 and 2009. Total annual expenditure on
dry eye treatment for year 2008 and 2009 were US$1,509,372.20
and US$1,520,797.80 respectively and total expenditure per
patient episode in year 2008 and 2009 were US$22.11 and
US$23.59 respectively. There was only 0.8% increase in total
annual expenditure from 2008 to 2009. However, expenditure per
patient episode had increased by 6.69% in year 2009, compared to
2008. This is despite the 5.56% decrease in the total number of
patients’ episodes from 2008 (68,278 episodes) to 2009 (64,480
episodes).
The unit costs of different dry eye treatments and their
categories are shown in Table 1. Figure 2A and B shows
quarterly expenditure for different types of treatment in dry eye for
2008 and 2009 respectively. Oral supplements in the form of
Thera TearsH (Advanced Vision Research, Inc., Woburn, MA,
USA, Ciba-Geigy Corporation, Tarrytown, NY 10591 USA) were
only available in pharmacy from last quarter of 2008. Table 2
shows the Mean quarterly expenditure in 2008 (column 1) and
2009 (column 2) stratified by the type of dry eye treatment. The
last column (Table 2) shows the expenditure per patient episode
by type of treatment, in other words, we divided the total
expenditure for each type of treatment by the number of episodes
involving that treatment over 2008–2009.
Cost per patient episode for pharmacological therapies
(Table 2, last column) such as TheratearsH oral supplements
and cyclosporine eye drops are relatively higher (US$80.27,
US$143.09) compared to conventional therapies such as MGD
therapy and lubricants (US$12.68, US$21.82). These forms of
treatment however may not necessarily be utilized over the same
duration of time. In order to examine the expenditure of same
duration, one can compare the expenditure for these items per
Table 1. The unit costs of dry eye treatments and their
categories.
Treatment category Unit Cost (US$)
Meibomian gland disease therapy
Lid-Care* 7.76
Blephagel* 10.7
Eye mask (hot/cold) 5.35
Preservative free lubricant eye drops
Refresh Plus eye drop
{ 15.16
Tears Naturale Free
{ 14.90
Refresh Ophthalmic Solution
{ 8.82
Preserved lubricant eye drops
Hypromellose 0.3% eye drop* 1.52
Tears Naturale II* 5.00
Refresh Tears* 6.65
Sodium Hyaluronate 0.1% (Hialid)* 8.88
Sodium Chloride 0.9% eye drop* 1.52
Fresh Tears* 5.35
Vidisept Ophtiole eye drop* 7.13
Hypo Tears eye drop* 3.30
Systane* 9.81
Liquifilm Tears* 5.88
Lubricant Ointments and gels
Vidisic eye gel
" 11.60
Duratears eye ointment
" 5.88
Solcoseryl 20% eye gel
" 5.35
Refresh Liquigel
" 8.92
Cyclosporin eye drops
Restasis 0.05% ophthalmic emulsion
{ 64.92
Oral Supplements
Thera Tears capsule* 43.69
Non Phamacological Treatments/Procedures
Punctum Cautery
{ 22.29
Punctum plug
{ 78.47
Tarsorrhaphy
{ 66.86
*Per bottle.
{Per 30 vials.
{Per procedure.
"Per tube.
doi:10.1371/journal.pone.0037711.t001
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lubricants are much higher compared to other types of treatments.
Note that the unit cost of medications didn’t change over the
period of the study (Table 1).
The relative expenditure of dry eye treatment by category is
shown in Figure 3 A (for 2008), B (2009) and C (2008–2009
overall). As in Figure 3C, Pharmacological treatment attributes to
99.2% of the total expenditure and lubricants accounts for 79.3%
of the total pharmacological treatment expenditure. Total number
of units purchased in the categories of preservative free lubricants,
0.05% topical cyclosporine emulsion and MGD therapy have
increased significantly (p,0.001) from 2008 to 2009 whereas the
Figure 1. Distribution of total monthly expenditure on dry eye treatment in 2008 and 2009.
doi:10.1371/journal.pone.0037711.g001
Figure 2. Distribution of quarterly expenditure among different treatment groups in 2008 & 2009. Figure 2A: Quarterly expenditure in
2008 Figure 2B: Quarterly expenditure in 2009.
doi:10.1371/journal.pone.0037711.g002
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gels have reduced significantly (p,0.001) (Table 3). The number
of surgical procedures in general was not significantly different
between 2008 and 2009(p=0.085). As oral supplement was only
available last quarter of 2008, this analysis was not possible for this
type of treatment.
Discussion
Seven major classes of dry eye treatment modalities currently
available in Singapore are, meibomian gland disease (MGD)
treatment, preservative free lubricant eye drops, preserved
lubricant eye drops, lubricant ointment and gels, anti-inflamma-
tory medication such as cyclosporine eye drops and non
pharmacological interventions such as punctum plugs, punctum
cautery and tarsorrhapy.
In our study, total expenditure of dry eye treatment between
2008 and 2009 were US$0.06 million per 1,000 patients and
pharmacological therapy was the major cost driver, accounting for
99.2% of total cost. In a previously published survey in US, on
2,171 respondents with dry eye which included both direct (cost of
consultation and treatment) and indirect costs (productivity loss
due to absenteeism and presenteeism) showed that average annual
cost of managing a patient with dry eye in US was US$783
(variation, US$757 to US$809) from the payers’ perspective.
When adjusted to the prevalence of dry eye nationwide, the overall
burden of the disease for the U.S. health-care system would be
US$3.84 billion and from a societal perspective, the average cost
of managing dry eye was estimated to be US$11,302 per patient
and US$55.4 billion to the U.S. society overall [10]. Another study
that involved 6 European countries (France, Germany, Italy,
Spain, Sweden and United Kingdom) showed that total annual
healthcare cost of 1,000 DES sufferers managed by ophthalmol-
ogists ranged from US$0.27million in France to US$1.10million in
UK [9]. These included the cost of specialist visits, diagnostic tests,
pharmacological and non pharmacological treatment. Specialist
visits were the primary cost driver in France, Germany and Spain
where as diagnostics test were the primary cost driver in Italy and
Sweden. In UK it was the prescription drugs. If we included the
cost per consultations (ranged from US$108.00 to US$58.00 per
visit), and diagnostic tests such as Schirmers (US$13.0 per test),
meibography (US$40.65 per test) which is much higher compared
to those European countries [9], and the indirect costs, annual
DES related healthcare expenditure in our settings is likely to be
much higher than estimated in this study.
It is also worth pointing out that Goods and Services Tax (GST)
of 7% of the selling price in government subsidized patients has
been absorbed by the institution. This would imply that the out of
pocket actual expenditure on dry eye could have been greater, if
patients were to purchase the same medications from a non-
hospital pharmacy in Singapore. Between 2008 and 2009 there
were a total of 58,469 subsidized patients’ visits (44% of total
recorded patients’ episodes).
Our study suggests that lubricant eye drops are the mainstay of
treatment for DES(67.1% of total PE) with a preference to
preserved eye drops (40.9% of total PE) (Figure 3D). The
lubricants with preservatives are much cheaper (mean unit cost
US$5.5062.81) compared to preservative free lubricants (mean
unit cost US$12.9663.59) and despite more episodes in this
category (54,357) compared to preservative free lubricant eye
drops (34,721), the overall expenditure is still lower in the
preserved category (Figure 3C).
The unit cost of preservative-free lubricant eye drops tends to be
more expensive than the preserved lubricant eye drops (Table 1).
In order to evaluate whether the private patients who are probably
financially better off than the subsidized patients, prefer the
preservative free eye drops, we performed Chi-square test to
evaluate the association of payment status of the patients with the
preservative status of the lubricant eye drops purchased over the
two years (2008–2009). Patients who did not qualify for the
government subsidy were considered as private patients. We found
that 53.3% of the pharmacy episodes of private patients were for
preservative free medications, but this was only 21.3% among the
subsidized patients (p,0.001). This shows that socioeconomic
factors may play a role in determining the type of dry eye
medications purchased by the patients. Previous studies have not
compared the relative expenditure of preservative free versus
preserved lubricants.
It is interesting to note that in our centre, the selling price of
monthly supply of Cyclosporine eye drops were much lesser
(US$64.92/patient) while cost of Thera TearsH oral supplement
were quite higher (US$43.69/patient) compared to a previously
published study in USA (US$115 and US$14 respectively) [2].
Table 2. Distribution of expenditure among different dry eye treatment groups.
Quarterly Expenditure in 2008
(US$) (Mean±SD)
Quarterly Expenditure in
2009 (US$) (Mean±SD)
Expenditure per Patient
Episode (US$)
Phamacological Treatments
Meibomian gland disease therapy 29509.5261936.56 30638.126681.97 12.68
Preservative free lubricant eye drops 155461.9066739.84 166837.4965176.30 37.10
Preserved lubricant eye drops 92848.4867311.95 76398.9863837.25 12.45
Lubricant ointments and gels 59384.3169477.15 49793.2962769.97 19.96
Cyclosporin eye drops 37747.6564262.05 43131.6864060.93 143.09
Oral Supplements 4063.325
{ 10704.1664828.84 80.27
Non Phamacological Treatments/Procedures
Punctum Cautery 122.60680.89 215.116101.97 25.49
Punctum plug 2501.126573.38 1634.146655.65 87.98
Tarsorrhaphy 790.446220.76 846.466436.12 72.75
{Oral supplements were only available in pharmacy from last quarter of 2008.
doi:10.1371/journal.pone.0037711.t002
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punctum occlusion and tarsorrhaphy were US$22.29, US$78.47
and US$66.86 per patient respectively, This is much less than in a
previously published US study (US$163, US$305 and US$464/
per patient respectively) [2].
The effects of punctum plugs, punctum cautery and tarsorrha-
phy might be more permanent compared to lubricants and may be
therefore more cost effective in the long term [11–13].
Study Limitations
It is possible that we underestimated the burden of DES
treatment because we excluded the data on cost of oral
Doxycycline, topical Fucithalmic and Tetracycline ointments
prescribed for meibomian gland disease and corticosteroids. We
did not include these data because we couldn’t ascertain the exact
diagnosis and indications for these treatments from our pharmacy
database,
Lubricants may have been used to treat conditions other than
dry eye. e.g. allergic conjunctivitis, recurrent corneal erosions and
exposure keratopathy. However, we assumed that proportions of
these conditions were probably low in our sample and would not
skew the results of this study. Previous study on use of eye care and
associated charges in US shows that case incidences of dry eye and
blepharitis attributed to 75 to 78% of the total case incidences of
external eye diseases [14].
Because of the unavailability of data, we didn’t include Non
pharmacological therapies e.g. humidifiers and complementary
and alternative medicine (CAM) therapies such as acupuncture
Figure 3. Relative expenditure & distribution of patient episodes of dry eye treatment categories in 2008 & 2009. Figure 3A. Relative
expenditure in 2008. Figure 3B. Relative expenditure in 2009. Figure 3C. Total expenditure in 2008 & 2009. Figure 3D: Distribution of patient
episodes in 2008 & 2009
doi:10.1371/journal.pone.0037711.g003
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has shown amount spent on CAM dry eye products ranges from
US$30 to US$2 per patient per month [15].
We didn’t estimate the cost of consultations which varies from
US$108 to US$58 per visit, in our analysis as our database didn’t
capture the exact diagnosis or purpose of a specific consultation
visit to dry eye clinic. Our study showed lower annual expenditure
compared to those studies that included physician consultation
charges [9,10,15]. One study showed up to .70% of total direct
costs were for physician consultations [15].
In our study, we didn’t consider the impact of severity of the
DES on total expenditure and the different prevalence of each
severity category. Previously published data showed that less
severe DES is more common [9,10]. DTS 2 and 1 are more
common than DTS 3). In severe cases, combination therapy (eg.
lubricants with punctum plugs and/or cyclosporine) is likely to be
used and the actual expenditure of DES management in these
more severe patients may have been higher than suggested in this
paper. In US annual expenditure of DES by severity per patient:
US$678 for mild DES, US$771 for moderate DES and US$1,267
for severe DES [10].
The data in this paper which only evaluated a hospital based
pharmacy may underestimate the national burden of DES since
some patients with dry eye may not come to hospital and either
self-treat themselves with over the counter lubricating eye drops or
are managed by general practitioners. Out of hospital pharmacies
in Singapore may also be more accessible to the general public in
terms of number of branches and locations. In previous cohort
studies, that only 11% of dry eye sufferers seek professional help.
Patients who self-diagnosed with dry eye, 57% purchased over the
counter drops [2,16]. Because of the recent economic downturn,
purchases of over the counter lubricants without visiting doctor’s
office might have increased over the period. To estimate the true
impact of recent economic downturn on cost and patterns of DES
expenditure, a larger population based study over several years is
required.
Previously published survey on 74 patients has shown an
estimated annual productivity loss of . US$5,000 per patient due
to dry eye. [17] In our study, we didn’t take indirect costs and
intangible costs such cost of travelling to doctor’s office for
consultation, cost loss of productivity and time into consideration
due to uncertainty of the accuracy of the data. Therefore total
societal costs borne by the patient is likely to be much higher.
Clinical Significance
Up to our knowledge there are no other studies published on the
cost of DES management in Asia. Our study demonstrate that
DES impose a direct burden to the health care expenditure and
given the limitations of the availability of socio-economic data in
our data sources, true costs of DES, borne by both the patient and
the government, are likely to be much higher. Outcome of this
study can be used in conjunction with clinical trials, and quality of
life studies to determine the cost effectiveness of the dry eye
treatment. It will also contribute to increase the awareness of
clinicians and policymakers on the importance of pursuing
cheaper and effective novel treatment modalities and improving
the existing public healthcare systems to reduce the financial
burden of DES on both patients and healthcare systems. Our data
seems to show lower expenditure compared to studies that
included physician consultation charges [15], suggesting that
national health care costs may be reduced if stable patients could
be managed by primary health care practitioners such as general
practitioners, optometrists or even self medicated.
In summary, DES seems to impose a substantial economic
burden to the health care expenditure in Singapore. In our centre,
mean costs of dry eye treatment per year is estimated to be
US$1,515,085.0068,079.12. Lubricants accounts for a large
proportion of the pharmacological expenditure and number of
units purchased on certain categories of treatment such as MGD
therapy, preservative free lubricants and cyclosporine eye drops
were shown to increase significantly over the period(P,0.01).
Given the limitations of the availability of socio-economic data in
our sources, true societal costs of DES are likely to be much higher
than estimated.
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